University of Wisconsin-Madison gene medicine developer Design Therapeutics has attracted SR One for its series A round.

Design Therapeutics, a US-based degenerative disorder medication developer spun out by University of Wisconsin-Madison, closed a $45m series A round on Friday led by SR One, the corporate venturing fund of pharmaceutical firm GlaxoSmithKline. Hedge fund manager Cormorant Asset Management, venture capital firm Quan Capital and investment group WestRiver also took part in the series…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.